Vivus found ED niche?; Cumberland IPO slammed;

  @FiercePharma: Bayer CEO-in-waiting aims for sales, not margins. Report | Follow @FiercePharma

>  Erectile dysfunction drugs should lose much of their luster in 2012 when generic versions of Pfizer's Viagra hit the market. But drugmaker Vivus seems to think it's found a new, viable niche--helping diabetics resolve ED concerns. Report

> Analysts really know how to hit a drugmaker where it hurts. In a new report, editor Jeff Reeves has slammed Cumberland Pharmaceuticals' IPO as the worst of the last 12 months. Article

> Indian generic drugmaker Orchid Chemicals and Pharmaceuticals has agreed to buy U.S.-based marketing firm Karalex Pharma LLC. The deal should add $20 million to Orchid's revenues this year and allow the Indian firm to directly market products in the U.S. Report

>  Endo Pharmaceuticals and Penwest Pharmaceuticals have settled a suit with Sandoz over rights to sell generic versions of the pain management drug Opana ER. Under the terms of the settlement, Sandoz will get a license to sell a generic version of Opana ER beginning in September 2012. Item

>  Over-the-counter genetic tests seem to be in demand, so much so that major drug chain Walgreens had set plans prepared to distribute them. The problem: the FDA may want to impose tighter regulations than expected on the tests, which could kill this niche. Article

>  Canadian health regulators have decided to make Pfizer include a boxed warning on packaging for smoking cessation drug Champix. The Health Canada agency says it wants to alert users to the drug's possible neuropsychiatric side effects. Item

Biotech News

 @FierceBiotech: Lasers used for painless injections. Report | Follow @FierceBiotech

 @JohnCFierce: For a 2012 insomnia drug, I suspect you'd need more than a placebo comparison to compete in the market. | Follow @JohnCFierce

> Head of Merck's new sleep drug class looks promising in IIb. Story

> Hospira gains EMA OK for Neupogen biosimilar. Report

> Igenica leads a trio of new venture rounds. Story

> Covance plans 300 hires for $15M storage ops. Article

> Icahn makes fresh inroads at Biogen and Genzyme. Item

> HGS files for FDA approval of breakthrough lupus drug. News

Vaccines News

> Vaccine myths fuel some stubborn consumer fears. Piece

> Experimental vax targets a key atherosclerosis trigger. Story

> WHO hits back over H1N1 conflict-of-interest claims. Article

Manufacturing News

> Xcellerex fast-tracks second single-use bioprocessing facility. Report

> Propofol vial reuse linked to hep C outbreak. Report

> Countries report flu vaccine inventory. News

> Nigerian agents detect fake drugs using Raman units. Story

> Lonza starts thinking lean with Raman. Article

And Finally...  Obviously, pharmaceutical companies invest in online marketing. The question is, just how much are they spending?  Item

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.